{
    "nctId": "NCT00416715",
    "briefTitle": "Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer",
    "officialTitle": "A Pilot Study of Vitamin D Deficiency and Myalgias, Arthralgias and/or Joint Stiffness Associated With Letrozole (Femara\u00ae )",
    "overallStatus": "COMPLETED",
    "conditions": "Arthralgia, Musculoskeletal Complications, Pain, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have a histologically confirmed diagnosis of Stage I, II or III breast carcinoma\n* Patients must be prescribed letrozole for adjuvant breast cancer treatment\n* Prior adjuvant tamoxifen is permitted\n* Patients must be postmenopausal; for study purposes, postmenopausal is defined as: a prior documented bilateral oophorectomy, or a history of at least 12 months without spontaneous menstrual bleeding, or have a persistently postmenopausal estradiol in the past 6 months without menses, and clinically in menopause at the judgment of the treating physician, or age 60 or older with a prior hysterectomy without oophorectomy, or age less than 60 with a prior hysterectomy without oophorectomy (or in whom the status of the ovaries is unknown), with a documented FSH level demonstrating confirmatory elevation in the postmenopausal range for the lab\n\nExclusion Criteria:\n\n* Diagnosis of Stage IV breast carcinoma\n* Pre-existing myalgias, arthralgias and/or joint stiffness \\>= Grade 1, as defined using CTEP CTC identified during baseline physical exam\n* Inability to understand or cooperate with study procedures\n* Receipt of investigational drug within 30 days before study entry\n* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome\n* Unwillingness to give informed consent\n* Unwillingness to participate or inability to comply with the protocol for the duration of the study\n* Patients with serum calcium \\>= 14 mg/dL\n* Patients with renal dysfunction defined as glomerular filtration rate \\<10ml/min calculated using Cockroft-Gault equation",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}